Identification

Generic Name
Inbakicept
DrugBank Accession Number
DB16479
Background

Not Available

Type
Biotech
Groups
Investigational
Synonyms
  • Inbakicept
External IDs
  • ALT-803
  • ALT803
  • N-803
  • WHO 1102

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Inbakicept is a human IL-15 superagonist with immunostimulatory properties. Though a promising anti-cancer biologic, the drug is also being investigated as an HIV cure. It has the ability to reactivate latent virus, and has the potential to enhance anti-viral immune repsonses in these chronic infections.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Cinchocaine.
CocaineThe risk or severity of methemoglobinemia can be increased when Inbakicept is combined with Cocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QN4LI58PJ5
CAS number
2135939-52-3

References

General References
  1. Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB: The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. doi: 10.1371/journal.ppat.1008339. eCollection 2020 Mar. [Article]
  2. McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, Silvestri G: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2Active Not RecruitingTreatmentCervical Cancer / Colorectal Cancer / Hepatocellular Carcinoma / Malignant Neoplasm of Stomach / Melanoma / Merkel Cell Carcinoma / Microsatellite Instability / Mismatch Repair-deficient (dMMR) / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Carcinoma / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN) / Urothelial Carcinoma1
2CompletedTreatmentAcute Myeloid Leukemia (AML)1
2CompletedTreatmentFIGO Stage III and IV Fallopian Tube Cancer / FIGO Stage III and IV Ovarian Cancer / FIGO Stage III Primary Peritoneal Cancer1
2Not Yet RecruitingPreventionLynch Syndrome1
2Not Yet RecruitingTreatmentCastration Resistant Prostate Cancer1
2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAdvanced HNSCC / Gastroesophageal Junction (GEJ) Cancers1
2RecruitingTreatmentColorectal Cancer / Small Bowel Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at January 21, 2021 01:47 / Updated at September 15, 2021 23:26